OncoMatch/Clinical Trials/NCT06971211

Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC

Is NCT06971211 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone. for metastatic castration-resistant prostate cancer.

Phase 2RecruitingJianbin BiNCT06971211Data as of May 2026

Treatment: Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone. — This study is an open label, single arm, multicenter clinical trial. The aim of this study is to evaluate the efficacy, safety, and quality of life of radiotherapy combined with Fuzuloparib and Abiraterone Acetate Tablets（Ⅱ） as first-line treatment for castration resistant prostate cancer patients. The study aims to enroll 40 eligible subjects with PSA response rate (PSA 50) as the primary endpoint.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: parp inhibitor (olaparib, nilaparib, terazopanib, lucaparib)

Lab requirements

Blood counts

ANC ≥ 1.5 × 10^9/L; PLT≥100×10^9/L; Hb≥90 g/L

Kidney function

Cr≤1.5×ULN

Liver function

TBIL ≤ 1.5 × ULN (excluding subjects with Gilbert syndrome); ALT and AST ≤ 2.5 × ULN

Cardiac function

LVEF≥50%; QTcF≤450 ms

The organ function level must meet the following requirements (no blood transfusion or hematopoietic growth factor therapy received within 2 weeks before blood routine screening): ANC ≥ 1.5 × 10^9/L PLT≥100×10^9/L； • Hb≥90 g/L； • TBIL ≤ 1.5 × ULN (excluding subjects with Gilbert syndrome) • ALT and AST ≤ 2.5 × ULN; • Cr≤1.5×ULN； • LVEF≥50%； • QTcF≤450 ms。

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify